目的 探討復(fù)方苦參注射液聯(lián)合SOX方案治療晚期胃癌患者的臨床療效。方法 選擇2018年3月—2022年2月成都市第五人民醫(yī)院收治的128例晚期胃癌患者，隨機(jī)將患者分為對(duì)照組和治療組，每組各64例。對(duì)照組給予SOX化療方案治療，其中靜脈滴注奧沙利鉑注射液，130 mg/m²加入250 mL 5%葡萄糖溶液中，第1天持續(xù)2 h；同時(shí)口服替吉奧膠囊，40 mg/次，2次/d，第1～14天。21 d為1個(gè)療程。治療組在對(duì)照組基礎(chǔ)上靜脈滴注復(fù)方苦參注射液，20 mL/次，用藥14 d、停藥7 d，3周為1個(gè)療程。兩組患者均治療4個(gè)療程。觀察兩組患者臨床療效，比較治療前后兩組患者血清腫瘤標(biāo)志物癌胚抗原（CEA）、糖類(lèi)抗原19-9（CA19-9）和糖類(lèi)抗原724（CA724）水平，及T淋巴細(xì)胞亞群CD3^＋、CD4^＋、CD8^＋、CD4^＋/CD8^＋水平。結(jié)果 治療后，治療組的客觀緩解率、疾病控制率分別是為78.13%、92.19%，明顯高對(duì)照組56.25%、79.69%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療后，兩組患者CEA、CA19-9、CA724和CD8^＋水平較治療前均明顯降低，而CD3^＋、CD4^＋和CD4^＋/CD8^＋水平明顯升高（P＜0.05），且治療組這些指標(biāo)明顯好于對(duì)照組（P＜0.05）結(jié)論 復(fù)方苦參注射液聯(lián)合SOX方案治療晚期胃癌臨床療效較好，能有效降低血清中的腫瘤標(biāo)志物水平，提升患者的免疫功能。

Objective To investigate the effects of Compound Kushen Injection combined with SOX chemotherapy regimen in treatment of advanced gastric cancer. Methods Patients (128 cases) with advanced gastric cancer in the Fifth People's Hospital of Chengdu from March 2018 to February 2022 were randomly divided into control group and treatment group, 64 cases in each group. Patients in the control group were administered with SOX chemotherapy regimen, 130 mg/m² of Oxaliplatin Injection added into 250 mL 5% glucose solution was injected intravenously for 2 h on the 1st day, and they were po administered with Gimeracil and Oteracil Potassium Capsules 40 mg/time, twice daily for 1 — 14 d, 21 d was a course of treatment. Patients in the treatment group were iv administered with Compound Kushen Injection on the basis of the control group, 20 mL/time, 14 days of medication, 7 days of withdrawal, 3 weeks as a course of treatment. Patients in two groups were treated for 4 courses of treatment. After treatment, the clinical evaluation was evaluated, and the levels of serum tumor markers CEA, CA19-9, and CA724, and the levels of T lymphocyte subsets CD3^＋, CD4^＋, CD8^＋, and CD4^＋/CD8^＋ in two groups before and after treatment were compared. Results After treatment, the objective remission rate and disease control rate of the treatment group were 78.13% and 92.19%, respectively, which were significantly higher than those of the control group 56.25% and 79.69%, and the difference between the two groups was statistically significant (P < 0.05). After treatment, the levels of CEA, CA19-9, CA724, and CD8^＋ in two groups were significantly lower than those before treatment, while the levels of CD3^＋, CD4^＋, and CD4^＋/CD8^＋ were significantly increased (P < 0.05), and these indexes in the treatment group were significantly better than those in the control group (P < 0.05).Conclusion Compound Kushen Injection combined with SOX chemotherapy regimen has a good clinical effect in the treatment of advanced gastric cancer, which can effectively reduce the level of tumor markers in serum and improve the immune function of patients.

R979.1